Nomura: Target price for Istone Pharma Group (01093.HK) is 8.02 Hong Kong dollars, rated as "buy"

Wisdom Finance APP learned that Nomura released a research report stating that the target price for Chi-Med (01093.HK) is 8.02 Hong Kong dollars, with a rating of "buy". The report points out that Chi-Med's performance in the first quarter of 2025 was weak, with a year-on-year decrease in revenue of 21.9% to 7 billion yuan (same below), lower than the expected 8.8 billion yuan, and a year-on-year decrease in profit of 8.4% to 1.5 billion yuan, also lower than the expected 2.4 billion yuan. The gross profit margin decreased by 5.2 percentage points year-on-year to 67.1%, with the gross profit margin of drug sales lower than expected by the bank, mainly due to unfavorable changes in product mix.